HRTX - Heron Therapeutics: Looking For Signs Of The Bottom

• After setbacks with the FDA, Heron finally launched Zynrelef in July with a constricted label to market. I believe Zynrelef might struggle in its first few quarters on the market.
• Heron is looking to broaden Zynrelef’s label with supplementary studies. In addition, the company has given Zynrelef a competitive price tag to help improve coverage.
• The Oncology Care Franchise is going to continue to be the primary breadwinner for the foreseeable future. The company is going to have to lean on these products for awhile.
• I take a look at the charts to identify a near-term bottom for my next HRTX buy.

For further details see: